Pharmacology of nivegacetor (RG6289), a potent and selective gamma secretase modulator in clinical development for the treatment of Alzheimer’s disease

BackgroundAlzheimer’s Disease (AD) is a prevalent neurodegenerative disorder which involves a complex pathobiology driven by amyloid-beta (Aβ) and tau pathologies, among other factors. Aβ peptides are generated via β-secretase (BACE1) and γ-secretase cleavage of amyloid precursor protein (APP). Whil...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Lothar Lindemann, Julie Lambotte, Judith Rothe, Jürg Messer, Catherine Diener, Solen Pichereau, Carina Cantrill, Thomas Mueggler, Michael Honer, Jennifer Beck, Thomas Steinbrecher, Rosanna Tortelli, Irene Gerlach, Hasane Ratni, Rosa Maria Rodriguez Sarmiento, Karlheinz Baumann
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Frontiers Media S.A. 2026-05-01
Rangatū:	Frontiers in Pharmacology
Ngā marau:	Alzheimer’s disease amyloid beta disease-modifying therapy gamma secrease modulator gamma secretase GSM
Urunga tuihono:	https://www.frontiersin.org/articles/10.3389/fphar.2026.1783414/full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!